Search Within

Izaskun Ceberio

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (4)
Groups
  1. Biostatistics Service (8)
  2. Bone Marrow Transplant (8)
  3. Center for Hematologic Malignancies (8)
  4. Department of Medicine (8)
  5. Epidemiology and Biostatistics (8)
  6. Hematologic Malignancies, Division of (8)

More Groups

People
  1. Miguel-Angel Perales (8)
  2. Sean Devlin (8)
  3. Hugo Castro-Malaspina (7)
  4. Juliet Barker (7)
  5. Sergio Giralt (7)
  6. Craig Sauter (5)

More People

Years
  1. 2017 (1)
  2. 2016 (3)
  3. 2015 (2)
  4. 2014 (1)
  5. 2013 (1)
Publications
  1. Biology of Blood and Marrow Transplantation (4)
  2. Bone Marrow Transplantation (3)
  3. Leukemia and Lymphoma (1)
Publishers
  1. Elsevier Inc. (4)
  2. Nature Publishing Group (3)
  3. Taylor & Francis Group (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hematopoietic cell transplantation comorbidity index predicts outcomes in patients with acute myeloid leukemia and myelodysplastic syndromes receiving CD34(+) selected grafts for allogeneic hematopoietic cell transplantation
    Journal Article

    Barba, P.; Ratan, R.; Cho, C.; Ceberio, I.; Hilden, P.; Devlin, S. M.; Maloy, M. A.; Barker, J. N.; Castro-Malaspina, H.; Jakubowski, A. A.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Sirolimus, tacrolimus and low-dose methotrexate as GVHD prophylaxis is safe and associated with promising results in patients receiving reduced-toxicity allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Avila, A. M.; Barba, P.; Cho, C.; Devlin, S.; Ceberio, I.; Ponce, D.; Maloy, M.; Perales, M. A.
    Bone Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts outcomes in patients with acute myeloid leukemia and myelodysplastic syndromes receiving CD34+ selected grafts for allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Barba, P.; Ratan, R.; Ceberio, I.; Hilden, P.; Devlin, S.; Maloy, M.; Barker, J.; Castro-Malaspina, H.; Jakubowski, A.; Koehne, G.; more...
    Bone Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts outcomes in patients with acute myeloid leukemia and myelodysplastic syndromes receiving CD34+ selected grafts for allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Barba, P.; Ratan, R.; Ceberio, I.; Hilden, P.; Maloy, M.; Barker, J. N.; Castro-Malaspina, H.; Jakubowski, A. A.; Koehne, G.; Papadopoulos, E.; more...
    Biology of Blood and Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT
    Journal Article

    Ceberio, I.; Dai, K.; Devlin, S. M.; Barker, J. N.; Castro-Malaspina, H.; Goldberg, J. D.; Giralt, S.; Adel, N. G.; Perales, M. A.
    Bone Marrow Transplantation (2015)

    Fulltext@MSK | Save
  • Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant
    Journal Article

    Ceberio, I.; Devlin, S. M.; Sauter, C.; Barker, J. N.; Castro-Malaspina, H.; Giralt, S.; Ponce, D. M.; Lechner, L.; Maloy, M. A.; Goldberg, J. D.; more...
    Leukemia and Lymphoma (2015)

    Fulltext@MSK | Save
  • A Phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with BCell lymphoid malignancies: Favorably durable event-free survival in chemosensitive patients
    Journal Article

    Sauter, C. S.; Barker, J. N.; Lechner, L.; Zheng, J.; Devlin, S. M.; Papadopoulos, E. B.; Perales, M. A.; Jakubowski, A. A.; Goldberg, J. D.; Koehne, G.; more...
    Biology of Blood and Marrow Transplantation (2014)

    Fulltext@MSK | Save
  • Delaying the start of triazole prophylaxis 7 days after allogeneic HCT does not affect outcomes, including risk of invasive fungal infection
    Meeting Abstract

    Dai, K. F.; Ceberio, I.; Devlin, S.; Barker, J. N.; Castro-Malaspina, H.; Goldberg, J.; Giralt, S. A.; Adel, N. G.; Perales, M. A.
    Biology of Blood and Marrow Transplantation (2013)

    Fulltext@MSK | Save